First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Schrödinger: the story is balanced — Software revenue growth rate and customer retention metrics (net dollar retention, new logo wins among top 20 pharma)
★ Analysts see FY2027 revenue reaching $265M — +13.0% growth in a single year.
What Moves the Stock
1Software revenue growth rate and customer retention metrics (net dollar retention, new logo wins among top 20 pharma)
2Internal pipeline clinical trial readouts (SGR-1505 MALT1 inhibitor, SGR-2921 CDC7 inhibitor) and IND filings
3New collaboration announcements with milestone payment structures and royalty terms
4Quarterly cash burn rate and runway visibility given negative FCF profile
5Competitive positioning updates versus Relay Therapeutics, Recursion Pharmaceuticals in AI-driven drug discovery space
6Software subscriptions (~60-70% of revenue): Physics-based molecular modeling platform licensed to pharma/biotech for drug discovery, materials science applications
7Drug discovery collaborations (~20-30%): Milestone payments and research funding from partnerships with companies like Bristol Myers Squibb, Takeda, Eli Lilly
8Internal drug development: Potential future royalties/milestone payments from proprietary pipeline (currently cost center, not revenue contributor)
growth - Attracts biotech/healthcare growth investors betting on platform adoption inflection and pipeline optionality.
High sensitivity through customer funding dynamics.
Watch on earnings: Quarterly software revenue run rate and y/y growth acceleration/deceleration, Net dollar retention rate for software customer base (target >110% for healthy SaaS business), Pipeline clinical trial enrollment rates and data readout timelines for SGR-1505, SGR-2921.
One Sentence Summary:
Schrödinger: the story is balanced — software revenue growth rate and customer retention metrics (net dollar retention, new logo wins among top 20 pharma).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.